| Id |
Subject |
Object |
Predicate |
Lexical cue |
| TextSentencer_T1 |
0-151 |
Sentence |
denotes |
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. |
| T1 |
0-151 |
Sentence |
denotes |
Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. |
| TextSentencer_T2 |
152-163 |
Sentence |
denotes |
BACKGROUND: |
| T2 |
152-163 |
Sentence |
denotes |
BACKGROUND: |
| TextSentencer_T3 |
164-293 |
Sentence |
denotes |
Recent evidence indicates that a subset of axillary node-negative (ANN) breast cancer patients can benefit from adjuvant therapy. |
| T3 |
164-293 |
Sentence |
denotes |
Recent evidence indicates that a subset of axillary node-negative (ANN) breast cancer patients can benefit from adjuvant therapy. |
| TextSentencer_T4 |
294-434 |
Sentence |
denotes |
Reliable prognostic markers are needed, however, to help clinicians identify these patients and arrive at more rational treatment decisions. |
| T4 |
294-434 |
Sentence |
denotes |
Reliable prognostic markers are needed, however, to help clinicians identify these patients and arrive at more rational treatment decisions. |
| TextSentencer_T5 |
435-443 |
Sentence |
denotes |
PURPOSE: |
| T5 |
435-443 |
Sentence |
denotes |
PURPOSE: |
| TextSentencer_T6 |
444-537 |
Sentence |
denotes |
Mutations of the p53 tumor suppressor gene often result in overexpression of the p53 protein. |
| T6 |
444-537 |
Sentence |
denotes |
Mutations of the p53 tumor suppressor gene often result in overexpression of the p53 protein. |
| TextSentencer_T7 |
538-659 |
Sentence |
denotes |
In this study, we evaluated the prognostic significance of p53 protein overexpression in patients with ANN breast cancer. |
| T7 |
538-659 |
Sentence |
denotes |
In this study, we evaluated the prognostic significance of p53 protein overexpression in patients with ANN breast cancer. |
| TextSentencer_T8 |
660-844 |
Sentence |
denotes |
We also studied the association between the tumor cell proliferation rate and overexpression of the p53 and c-erbB-2 proteins, both of which have been implicated in cell cycle control. |
| T8 |
660-844 |
Sentence |
denotes |
We also studied the association between the tumor cell proliferation rate and overexpression of the p53 and c-erbB-2 proteins, both of which have been implicated in cell cycle control. |
| TextSentencer_T9 |
845-899 |
Sentence |
denotes |
The c-erbB-2 protein is the product of the ERBB2 gene. |
| T9 |
845-899 |
Sentence |
denotes |
The c-erbB-2 protein is the product of the ERBB2 gene. |
| TextSentencer_T10 |
900-908 |
Sentence |
denotes |
METHODS: |
| T10 |
900-908 |
Sentence |
denotes |
METHODS: |
| TextSentencer_T11 |
909-1085 |
Sentence |
denotes |
Two hundred eighty-nine ANN cases were randomly selected from a population-based cohort of patients who had not received any kind of adjuvant chemotherapy or endocrine therapy. |
| T11 |
909-1085 |
Sentence |
denotes |
Two hundred eighty-nine ANN cases were randomly selected from a population-based cohort of patients who had not received any kind of adjuvant chemotherapy or endocrine therapy. |
| TextSentencer_T12 |
1086-1291 |
Sentence |
denotes |
Overexpression of the p53 and c-erbB-2 proteins was studied immunohistochemically in archival paraffin-embedded tumor samples, using the CM-1 polyclonal and the TAb 250 monoclonal antibodies, respectively. |
| T12 |
1086-1291 |
Sentence |
denotes |
Overexpression of the p53 and c-erbB-2 proteins was studied immunohistochemically in archival paraffin-embedded tumor samples, using the CM-1 polyclonal and the TAb 250 monoclonal antibodies, respectively. |
| TextSentencer_T13 |
1292-1385 |
Sentence |
denotes |
The tumor cell proliferation rate was measured as the S-phase fraction by DNA flow cytometry. |
| T13 |
1292-1385 |
Sentence |
denotes |
The tumor cell proliferation rate was measured as the S-phase fraction by DNA flow cytometry. |
| TextSentencer_T14 |
1386-1442 |
Sentence |
denotes |
Statistical analyses were performed using BMDP software. |
| T14 |
1386-1442 |
Sentence |
denotes |
Statistical analyses were performed using BMDP software. |
| TextSentencer_T15 |
1443-1451 |
Sentence |
denotes |
RESULTS: |
| T15 |
1443-1451 |
Sentence |
denotes |
RESULTS: |
| TextSentencer_T16 |
1452-1697 |
Sentence |
denotes |
High-level p53 protein overexpression, found in 41 of the 289 tumors, was most common in tumors with high histologic grade, negative estrogen receptor status, c-erbB-2 protein overexpression, DNA index greater than 1.3, or high S-phase fraction. |
| T16 |
1452-1697 |
Sentence |
denotes |
High-level p53 protein overexpression, found in 41 of the 289 tumors, was most common in tumors with high histologic grade, negative estrogen receptor status, c-erbB-2 protein overexpression, DNA index greater than 1.3, or high S-phase fraction. |
| TextSentencer_T17 |
1698-1898 |
Sentence |
denotes |
The lowest S-phase levels were found in tumors with neither p53 nor c-erbB-2 protein overexpression; the highest levels were seen in tumors showing overexpression of both proteins (P less than .0001). |
| T17 |
1698-1898 |
Sentence |
denotes |
The lowest S-phase levels were found in tumors with neither p53 nor c-erbB-2 protein overexpression; the highest levels were seen in tumors showing overexpression of both proteins (P less than .0001). |
| TextSentencer_T18 |
1899-2018 |
Sentence |
denotes |
Both p53 and c-erbB-2 overexpression, as well as tumor size, had independent prognostic value in multivariate analysis. |
| T18 |
1899-2018 |
Sentence |
denotes |
Both p53 and c-erbB-2 overexpression, as well as tumor size, had independent prognostic value in multivariate analysis. |
| TextSentencer_T19 |
2019-2184 |
Sentence |
denotes |
Eight-year survival of patients with p53 protein overexpression was 56% compared with 81% in patients with no overexpression (relative risk, 3.7; P less than .0001). |
| T19 |
2019-2184 |
Sentence |
denotes |
Eight-year survival of patients with p53 protein overexpression was 56% compared with 81% in patients with no overexpression (relative risk, 3.7; P less than .0001). |
| TextSentencer_T20 |
2185-2352 |
Sentence |
denotes |
If the S-phase fraction was included in a Cox regression analysis, however, only the tumor size and the S-phase fraction emerged as independent predictors of survival. |
| T20 |
2185-2352 |
Sentence |
denotes |
If the S-phase fraction was included in a Cox regression analysis, however, only the tumor size and the S-phase fraction emerged as independent predictors of survival. |
| TextSentencer_T21 |
2353-2365 |
Sentence |
denotes |
CONCLUSIONS: |
| T21 |
2353-2365 |
Sentence |
denotes |
CONCLUSIONS: |
| TextSentencer_T22 |
2366-2562 |
Sentence |
denotes |
Overexpression of the p53 and c-erbB-2 proteins indicates a high malignant potential in ANN breast cancer, but it is not a significant prognostic factor independent of the cell proliferation rate. |
| T22 |
2366-2562 |
Sentence |
denotes |
Overexpression of the p53 and c-erbB-2 proteins indicates a high malignant potential in ANN breast cancer, but it is not a significant prognostic factor independent of the cell proliferation rate. |
| TextSentencer_T23 |
2563-2734 |
Sentence |
denotes |
The correlation between overexpression of these proteins and an increased S-phase fraction suggests that they may confer a proliferative advantage to cancer cells in vivo. |
| T23 |
2563-2734 |
Sentence |
denotes |
The correlation between overexpression of these proteins and an increased S-phase fraction suggests that they may confer a proliferative advantage to cancer cells in vivo. |